Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Research output: Contribution to journal › Journal article › Research › peer-review
On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.
| Original language | English |
|---|---|
| Journal | Lancet Neurology |
| Volume | 10 |
| Issue number | 4 |
| Pages (from-to) | 329-37 |
| Number of pages | 9 |
| ISSN | 1474-4422 |
| DOIs | |
| Publication status | Published - 2011 |
ID: 40198084